Abstracts tagged "Disease Activity and rheumatoid arthritis"

Abstract Number: 2428 • 2014 ACR/ARHP Annual Meeting
Comparative Study of Rheumatoid Arthritis Disease Activity Indices in Two Populations of Meteor Database
Helena Canhão¹, Fernando Magalhaes Martins², Jose Antonio Melo Gomes³, Maria Jose Santos⁴, Augusto Faustino⁵, José Antonio Costa⁶, Cornelia Allaart⁷, E. Gvozdenovic⁸, Pedro Machado⁹, Jaime C. Branco¹⁰, João E. Fonseca¹¹ and José Pereira Da-Silva¹², ¹Av. Prof. Egas Moniz, Hospital Santa Maria, Lisboa, Portugal, ²Portuguese Society of Rheumatology, Lisbon, Portugal, ³Instituto Português de Reumatologia, Lisbon, Portugal, ⁴Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁵Clínica de Reumatologia de Lisboa, Lisbon, Portugal, ⁶Rheumatology, Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, ⁷Rheumatology, Leiden Univ Med Ctr, Leiden, Netherlands, ⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, ¹⁰Rheumatology, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, ¹¹Lisbon Academic Medical Center, Lisbon, Portugal, ¹²Rheumatology, Hospitais da Universidade de Coimbra, Coimbra, Portugal
Background/Purpose Our aims were to assess disease activity states using DAS28ESR, CDAI and SDAI and to compare their outcomes in two rheumatoid arthritis (RA) populations…
Abstract Number: 378 • 2014 ACR/ARHP Annual Meeting
The Use of Week 12 CDAI, RAPID3 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate
Gerd Burmester¹, Gurjit S. Kaeley², Jeffrey R. Curtis³, Yusuf Yazici⁴, Benoit Guerette⁵, Xin Wang⁵, Alan Friedman⁵ and Vibeke Strand⁶, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²College of Medicine, University of Florida, Jacksonville, FL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵AbbVie, Inc., North Chicago, IL, ⁶Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose The prediction of treatment outcomes based on early response could guide treatment decisions in patients (pts) with rheumatoid arthritis (RA). The objective was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].